Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA

Key Points

• Dimensional Fund Advisors cut its Vanda Pharmaceuticals stake by 16.4% in the first quarter, selling 346,835 shares and retaining 1.77 million shares worth approximately $12.24 million. Institutional investors and hedge funds collectively own 88.14% of VNDA.
• Vanda reported weaker-than-expected quarterly results, with an adjusted loss of $1.04 per share versus the $0.58 consensus estimate and revenue of $50.53 million compared with expectations of $61.92 million.
• VNDA opened at $5.00, near its 52-week low, while analyst sentiment remains mixed but averages to a “Moderate Buy” rating with a consensus price target of $14.30.

Dimensional Fund Advisors LP reduced its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 16.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,771,593 shares of the biopharmaceutical company's stock after selling 346,835 shares during the period. Dimensional Fund Advisors LP owned 2.95% of Vanda Pharmaceuticals worth $12,240,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Torren Management LLC purchased a new stake in Vanda Pharmaceuticals in the fourth quarter valued at approximately $25,000. Russell Investments Group Ltd. raised its stake in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 5,328 shares during the period. Quarry LP acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $53,000. Cerity Partners LLC acquired a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $69,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $72,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Price Performance

VNDA opened at $5.00 on Friday. Vanda Pharmaceuticals Inc. has a 52-week low of $4.15 and a 52-week high of $9.94. The company has a 50 day moving average of $5.78 and a two-hundred day moving average of $6.75. The company has a market cap of $300.65 million, a P/E ratio of -1.08 and a beta of 0.64. The company has a quick ratio of 2.15, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.46). The business had revenue of $50.53 million during the quarter, compared to analysts' expectations of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. On average, analysts expect that Vanda Pharmaceuticals Inc. will post -2.2 earnings per share for the current year.

Wall Street Analyst Weigh In

VNDA has been the subject of a number of research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. HC Wainwright reiterated a "buy" rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Finally, Wall Street Zen downgraded Vanda Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vanda Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $14.30.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source